Zytoprotec Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $569K

  • Investors
  • 2

Zytoprotec General Information

Description

Developer of a biotechnology platform designed to develop peritoneal dialysis fluid for the treatment of kidney failure in patients. The company's platform develops a product that is based on a protected cytoprotective compound that helps in restoring the protective mechanism of cells, enabling physicians to decrease kidney failure and improve the quality of life and the survival of patients.

Contact Information

Website
www.zytoprotec.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Mariannengasse 28/2
  • Vienna, 1090
  • Austria
+43 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Mariannengasse 28/2
  • Vienna, 1090
  • Austria
+43 01

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zytoprotec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 01-Jan-2019 $569K Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A2) 01-Jan-2016 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 29-Jan-2013 $2.66M $11.5M Completed Clinical Trials - Phase 2
1. Early Stage VC 01-Jan-2011 $8.86M $8.86M Completed Startup
To view Zytoprotec’s complete valuation and funding history, request access »

Zytoprotec Patents

  • 20

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Zytoprotec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4424307-A1 Protective agent for use in peritoneal dialysis Pending 03-Mar-2023
ES-2746056-T3 Peritoneal dialysis fluid comprising a gsk-3 inhibitor Active 27-Dec-2011
US-9968636-B2 Peritoneal dialysis fluid comprising a gsk-3 inhibitor Active 27-Dec-2011
US-20150004255-A1 Peritoneal dialysis fluid comprising a gsk-3 inhibitor Active 27-Dec-2011
CA-2859064-A1 Peritoneal dialysis fluid comprising a gsk-3 inhibitor Active 27-Dec-2011 A61K33/14
To view Zytoprotec’s complete patent history, request access »

Zytoprotec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zytoprotec Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Horizon 2020 Government
Baxter Ventures Corporate Venture Capital Minority
To view Zytoprotec’s complete investors history, request access »

Ready to get started?

Request a free trial

Zytoprotec FAQs

  • When was Zytoprotec founded?

    Zytoprotec was founded in 2007.

  • Where is Zytoprotec headquartered?

    Zytoprotec is headquartered in Vienna, Austria.

  • What is the size of Zytoprotec?

    Zytoprotec has 10 total employees.

  • What industry is Zytoprotec in?

    Zytoprotec’s primary industry is Drug Discovery.

  • Is Zytoprotec a private or public company?

    Zytoprotec is a Private company.

  • What is Zytoprotec’s current revenue?

    The current revenue for Zytoprotec is .

  • How much funding has Zytoprotec raised over time?

    Zytoprotec has raised $20.5M.

  • Who are Zytoprotec’s investors?

    Horizon 2020 and Baxter Ventures have invested in Zytoprotec.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »